Iruplinalkib showed the lowest incidence of hematological AEs (72.2%), and alectinib (600 mg bid) had the lowest risk of gastrointestinal AEs (78.6%).<h4>Conclusions</h4>Lorlatinib demonstrated PFS advantage for advanced ALK rearrangement NSCLC, but OS benefit remains unestablished. Here, ALK is linked to non-small cell lung carcinoma.